Jan 25, 2013 by Brandy BetzA Late-Stage Threshold for Success? Will Threshold's pancreatic drug fair better in phase 3 trials?
Jan 23, 2013 by Brandy BetzMAP Gets Inhaled by AllerganAllergan acquires MAP for its pending migraine inhalant.
Jan 22, 2013 by Brandy BetzWhat's Next for Affymax? Affymax prepares to take on Amgen's 20-year hold on the dialysis market.
Jan 18, 2013 by Brandy Betz3 Things to Watch at Alkermes Alkermes has settled in after acquiring Elan's drug discovery unit -- what's next?
Jan 18, 2013 by Brandy Betz3 Things to Watch at Alkermes Alkermes has settled in after acquiring Elan's drug discovery unit -- what's next?
Jan 16, 2013 by Brandy BetzWhat's Ahead for Ariad?Iclusig's approval leaves investors asking, "What's next?"
Jan 11, 2013 by Brandy BetzJPMorgan Healthcare Conference Rewind: Rigel PharmaceuticalsDoes the clinical-stage company have a strong pipeline to back a faltering lead?
Jan 10, 2013 by Brandy BetzBioMarin's Big Week BioMarin acquired a company and highlighted a promising pipeline.
Jan 9, 2013 by Brandy BetzVertex: The Year Ahead How will Vertex adjust for lead drug losses in 2012?
Jan 7, 2013 by Brandy Betz3 Health Care Companies I'm Watching TodayThree companies worth watching at the J.P. Morgan Healthcare Conference.
Jan 4, 2013 by Brandy BetzAbbVie's Born -- What Now? The Abbott spinoff has a one-drug dependence it needs to watch.
Jan 3, 2013 by Brandy BetzAnother ALS Drug Failure for the Pile Biogen cancels ALS drug that flunked phase 3 trial.
Dec 31, 2012 by Brandy BetzVIVUS Wraps Up Pivotal YearQsymia made it to the market this year and met a tepid reaction. What's next?
Dec 31, 2012 by Brandy BetzThe Top Pharma Acquisitions of 2012Two deals stood out this year and hinted at a continuing trend in pharma.
Dec 29, 2012 by Brandy BetzTop Alzheimer's Missteps of 2012Could Alzheimer's drug failures from Eli Lilly and Johnson & Johnson spell trouble for Merck?
Dec 27, 2012 by Brandy Betz3 Things to Watch at Merrimack Two promising drugs and a big pharma backer make this small cap worth noticing.
Dec 26, 2012 by Brandy Betz3 Drug Disappointments From 2012 Three drugs popped investor optimism this year and will still make waves in 2013.
Dec 20, 2012 by Brandy Betz3 Things to Watch at Isis PharmaceuticalsWith lead drug Kynamro in question, what's next for Isis?
Dec 18, 2012 by Brandy Betz1 Way to Jazz Up This Pharma Stock Bolstering its lead drug is the "make or break" for Jazz Pharmaceuticals.
